Isa-VRd is an effective “quadruplet” (4-drug) regimen that combines medicines from 4 drug classes: the monoclonal antibody Sarclisa® (isatuximab-irfc) + the proteasome inhibitor Velcade® (bortezomib) + the immunomodulatory agent Revlimid® (lenalidomide) + the steroid dexamethasone. In September 2024, the U.S. Food and Drug Administration (FDA) approved the use of Isa-VRd for patients with newly diagnosed multiple myeloma (NDMM) who are not eligible for autologous stem cell transplant (ASCT).
